Correct Answer: C. Bethanechol
Postoperative urinary retention is a functional obstruction caused by loss of detrusor muscle tone and impaired micturition reflex, not anatomical obstruction. Bethanechol is a selective M3 muscarinic agonist that directly stimulates the detrusor muscle of the bladder, increasing intravesical pressure and promoting voiding. Unlike other agents, bethanechol has minimal systemic effects due to poor absorption and rapid metabolism, making it safe for short-term use in postoperative settings. The drug is particularly suitable here because: (1) it directly restores detrusor contractility without blocking alpha-adrenergic receptors, (2) it has a rapid onset (30–90 minutes) and short duration (4–6 hours), ideal for acute retention, and (3) it avoids the prolonged effects of alpha-blockers. In Indian clinical practice, bethanechol (0.25–0.5 mg SC/IM or 25–50 mg oral) is the standard short-term agent for postoperative and neurogenic urinary retention. The patient's COPD and diabetes are relevant because alpha-blockers (terazosin, tamsulosin) can cause orthostatic hypotension and worsen glycemic control, while anticholinergics are contraindicated. Bethanechol's cholinergic action is safe in this context as it has no systemic anticholinergic effects.
Why the other options are wrong
A. Terazosin — Terazosin is a long-acting alpha-1 blocker designed for chronic BPH, not acute postoperative retention. It causes prolonged vasodilation and orthostatic hypotension—particularly dangerous in a diabetic patient with autonomic neuropathy. Its onset is slow (hours to days) and duration is 12–16 hours, unsuitable for short-term acute management. Alpha-blockers are contraindicated in postoperative retention because they worsen detrusor contractility rather than restore it. B. Methacholine — Methacholine is a non-selective muscarinic agonist that causes widespread cholinergic effects including bronchospasm, increased salivation, and severe bradycardia. It is absolutely contraindicated in COPD as it triggers acute bronchospasm and respiratory compromise. Methacholine is used only as a diagnostic agent in asthma challenge testing, never therapeutically. This is a classic NBE trap pairing a cholinergic drug with COPD to test contraindication awareness. D. Tamsulosin — Tamsulosin is a selective alpha-1A blocker approved for chronic BPH management, not acute postoperative retention. Like terazosin, it causes orthostatic hypotension and has a prolonged half-life (5–7 hours), making it unsuitable for short-term use. Alpha-blockers relax the urethral sphincter but do not increase detrusor contractility, so they cannot overcome the atonic bladder in postoperative retention. Chronic use also risks worsening glycemic control in diabetics.
High-Yield Facts
- Bethanechol is the drug of choice for acute postoperative and neurogenic urinary retention due to selective M3 muscarinic stimulation of detrusor muscle.
- Methacholine is contraindicated in COPD because non-selective muscarinic agonism causes bronchospasm and respiratory failure.
- Alpha-blockers (terazosin, tamsulosin) are for chronic BPH, not acute retention; they relax urethral sphincter but do not restore detrusor contractility.
- Bethanechol dosing: 0.25–0.5 mg SC/IM or 25–50 mg oral; onset 30–90 min, duration 4–6 hours—ideal for short-term acute management.
- Anticholinergics worsen urinary retention; bethanechol's cholinergic action is therapeutic and safe in postoperative settings without systemic side effects.
Mnemonics
CHOLINE for Retention Cholinergic agonist (bethanechol) for acute retention; Histamine/H2 blockers irrelevant; Other agents (alpha-blockers) for chronic BPH; Long-term management differs; Inhibitors (anticholinergics) worsen it; Non-selective (methacholine) contraindicated in COPD; Early intervention with bethanechol. SHORT-TERM vs LONG-TERM SHORT-TERM acute retention → Bethanechol (muscarinic agonist, 4–6 hr duration). LONG-TERM BPH → Alpha-blockers (terazosin, tamsulosin, 12+ hr duration). Use this to eliminate alpha-blockers in postoperative questions.
NBE Trap
NBE pairs methacholine (a cholinergic drug) with COPD to trap students who recognize "cholinergic = bladder contraction" but forget that non-selective muscarinic agonism causes bronchospasm. The trap tests whether students know bethanechol's selectivity for M3 and methacholine's lack of selectivity, not just the drug class.
Clinical Pearl
In Indian tertiary care, bethanechol is routinely used in postoperative wards for acute retention after spinal anesthesia or general anesthesia. A diabetic patient with COPD is at high risk for orthostatic complications with alpha-blockers, making bethanechol's lack of systemic vasodilation a critical safety advantage. Always ask: "Is this acute (bethanechol) or chronic (alpha-blocker)?" in retention questions.
_Reference: KD Tripathi Ch. 6 (Cholinergic Drugs); Harrison Ch. 47 (Urinary Retention); Robbins Ch. 20 (Postoperative Complications)_